MPT Funding Opportunities

We continue to identify and share funding opportunities as they arise to help advance the MPT field. Funding opportunities are listed starting with the anticipated opportunities, then earliest upcoming application due dates. We encourage you to browse the below and welcome you to This email address is being protected from spambots. You need JavaScript enabled to view it. if you hear of any new opportunities.


Social and Behavior Change Research Award

USAID is seeking to strengthen the generation and utilization of evidence on social and behavior change programming that addresses agency of individuals and communities to improve the uptake and continuation of healthy behaviors, including family planning and reproductive health (FP/RH), maternal and child health (MCH), nutrition, and/or other outcomes. This includes socio-behavioral research around desirability and acceptability of MPT products.

Additional details can be found at USAID Business Forecast Search and searching within “Title/Description/A&A Plan ID” for Award Opportunity: AA-312481, then hit enter.

  • A&A Plan ID: AA-312481
  • Anticipated Release Date: 26 February 2021
  • Letters of Intent Due: TBD
  • Application Due: TBD

 The Microbicide 2021 Introduction and Access Project

The objective of USAID’s Microbicide 2021 Introduction and Access Project is to ensure that women can prevent HIV acquisition by accelerating the introduction and scale-up of biomedical products for HIV prevention, especially those products that are new or for which regulatory approval is imminent, and to expedite their availability, acceptance, uptake, and impact in PEPFAR programs. This includes MPTs that prevent HIV, other sexually transmitted infections (STIs), and/or unintended pregnancy.

Additional details can be found at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: 7200AA21RFA00008, then clicking on the opportunity number.

  • Funding Opportunity #: 7200AA21RFA00008
  • Open Date: 27 January 2021
  • Letters of Intent Due: NA
  • Application Due: 28 March 2021

NIH HIV Prevention Trials Network

The HPTN is calling for new research concepts from HPTN and non-HPTN affiliated investigators. Submissions that fit HPTN’s mission, objectives, and scientific priorities as well as address any of the research pillars below will be considered. Learn more!

  • Identifying novel antiretroviral (ARV)-based methods and delivery systems for HIV prevention
  • Developing multipurpose prevention technologies for HIV prevention as well as for contraception, prevention of other sexually transmitted infections or opioid dependence
  • Evaluating broadly neutralizing antibodies alone or in a combination that prevent HIV acquisition, in collaboration with the HIV Vaccine Trials Network
  • Designing and conducting population-specific integrated strategy studies that combine biomedical, socio-behavioral, and structural interventions for HIV prevention to maximize their effectiveness
  • Funding Opportunity #: NA
  • Open Date: 11 January 2021
  • Letters of Intent Due: 1 March 2021
  • Application Due: 5 April 2021

Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)

The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing male or female non-hormonal contraception development with the capabilities and capacity for pre-clinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism, fertility studies).

This opportunity aims to position innovative and validated methods for future clinical development. The long-term objective is the enablement of an IND/IDE study of a pre-clinical candidate that offers a safe non-hormonal based therapy for male and/or female contraception, including contraceptive MPTs, that acts prior to fertilization and does not act via the hypothalamic-pituitary-gonadal axis.

Applicants DO NOT need to be currently funded to receive support, though funded grantees may be given priority.

Additional details can be found at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-19-261, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-19-261
  • Open Date: 1 June 2019
  • Letters of Intent Due: 3 April 2021, 13 November 2021
  • Application Due: 3 May 2021, 13 December 2021

Biological Testing Facility (X01 Clinical Trial Not Allowed)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development’s (NICHD) state-of-the art Biological Testing Facility supports female and/or male non-hormonal contraception development, including MPTs. This opportunity is to support the enablement of an IND/IDE study of a pre-clinical candidate that offers a safe, non-hormonal based therapy for female and/or male contraception that acts prior to fertilization and does not act via the hypothalamic-pituitary-gonadal axis. Additional details can be found at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-21-078, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-21-078
  • Open Date: 15 December 2020
  • Letters of Intent Due: Not Applicable
  • Application Due: 15 July 2021, 14 January 2022, 15 July 2022

Contraception Development Research Center Program (P50 Clinical Trial Optional)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for women and men through the formation of a Contraceptive Research Development Center. The NICHD is accepting applications including translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success and sociobehavioral and market research to test user acceptability for contraceptive products being developed. The Center will also serve as a national resource for development of early-stage investigators electing to pursue careers in contraceptive research. Applications focused on the late-stage pre-clinical development or clinical development of a single non-hormonal MPT with both contraceptive and anti-infective properties are of high priority. Additional details can be found at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: RFA-HD-22-003, then clicking on the opportunity number.

  • Funding Opportunity #: RFA-HD-22-003
  • Open Date: 28 February 2021
  • Letters of Intent Due: 29 October 2021
  • Application Due: 29 November 2021

Family Planning and Reproductive Health Methods APS

The United States Agency for International Development (USAID) is seeking to support the research, development, and introduction of technologies and approaches that better meet the needs of women as their sexual and reproductive health concerns change over time. This includes the development of multipurpose prevention technologies (MPTs) that address the simultaneous risks of unintended pregnancy, HIV, and other sexually transmitted infections (STIs)—particularly Herpes Simplex Virus (HSV) and Human Papillomavirus (HPV). Additional details can be found on the Round 4 call for concept papers at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: SOL-OAA-13-000024, then clicking on the opportunity number.

  • Funding Opportunity #: SOL-OAA-13-000024
  • Open Date: 15 January 2013
  • Concept Papers Due: 14 February 2020
  • Application Due: 14 January 2023

Resource Search

 
 
Keyword Search
 

657 resource(s) found

The IMPT is the first & only initiative dedicated to advancing the field of multipurpose prevention technologies (MPTs), products that combine HIV prevention, other STI prevention, and contraception.

IMPT Secretariat
1750 Howe Avenue, Suite 550
Sacramento, CA 95825
IMPT@cami-health.org

The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
© Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.